These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 12031682

  • 1. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
    Ranjan M, Diffley P, Stephen G, Price D, Walton TJ, Newton RP.
    Life Sci; 2002 May 31; 71(2):115-26. PubMed ID: 12031682
    [Abstract] [Full Text] [Related]

  • 2. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B.
    Chin Med J (Engl); 2013 Feb 31; 126(4):711-5. PubMed ID: 23422194
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2.
    Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ, Metcalf BW.
    J Steroid Biochem Mol Biol; 1994 Feb 31; 48(2-3):197-206. PubMed ID: 8142295
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT.
    Endocrinology; 2004 Dec 31; 145(12):5420-8. PubMed ID: 15308613
    [Abstract] [Full Text] [Related]

  • 9. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J.
    J Androl; 2003 Dec 31; 24(5):681-7. PubMed ID: 12954658
    [Abstract] [Full Text] [Related]

  • 10. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS.
    J Urol; 1999 Jan 31; 161(1):332-7. PubMed ID: 10037433
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb 31; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 13. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
    Flores E, Cabeza M, Quiroz A, Bratoeff E, García G, Ramírez E.
    Steroids; 2003 Mar 31; 68(3):271-5. PubMed ID: 12628690
    [Abstract] [Full Text] [Related]

  • 14. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ, Rittmaster RS.
    J Urol; 2008 Apr 31; 179(4):1235-42. PubMed ID: 18280514
    [Abstract] [Full Text] [Related]

  • 15. Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5alpha-reductase.
    McNulty AM, Audia JE, Bemis KG, Goode RL, Rocco VP, Neubauer BL.
    J Steroid Biochem Mol Biol; 2000 Apr 31; 72(1-2):13-21. PubMed ID: 10731633
    [Abstract] [Full Text] [Related]

  • 16. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, Panzeri A, Délos S, Martin PM.
    J Steroid Biochem Mol Biol; 1998 Feb 31; 64(3-4):179-86. PubMed ID: 9605412
    [Abstract] [Full Text] [Related]

  • 17. CGP 53153: a new potent inhibitor of 5alpha-reductase.
    Häusler A, Allegrini PR, Biollaz M, Batzl C, Scheidegger E, Bhatnagar AS.
    J Steroid Biochem Mol Biol; 1996 Feb 31; 57(3-4):187-95. PubMed ID: 8645628
    [Abstract] [Full Text] [Related]

  • 18. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
    Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Leibovitch IY, Krushinski JH, Lee C, Steidle CP, Sutkowski DM, Neubauer BL.
    J Steroid Biochem Mol Biol; 1996 May 31; 58(2):195-205. PubMed ID: 8809201
    [Abstract] [Full Text] [Related]

  • 19. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P.
    Adv Ther; 2010 Aug 31; 27(8):555-63. PubMed ID: 20623347
    [Abstract] [Full Text] [Related]

  • 20. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
    Youn DH, Park J, Kim HL, Jung Y, Kang J, Jeong MY, Sethi G, Seok Ahn K, Um JY.
    Oncotarget; 2017 Feb 07; 8(6):9500-9512. PubMed ID: 27880726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.